A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06062069

Title field or adapter rule

{'original_value': 'A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-29T01:00:17.693027+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Results Posted At

2026-10-28

Source Retrieved At

2026-10-29T01:00:16.864611+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Overweight", "Obese", "Type 1 Diabetes Mellitus"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06062069"

protocolSection.identificationModule.officialTitle

"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

Study condition terms

• Overweight (protocolSection.conditionsModule.conditions)
• Obese (protocolSection.conditionsModule.conditions)
• Type 1 Diabetes Mellitus (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['CT-868 High Dose', 'CT-868 Low Dose', 'CT-868 Medium Dose'], 'description': 'CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.', 'name': 'CT-868', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['CT-868 High Dose', 'CT-868 Low Dose', 'CT-868 Medium Dose', 'CT-868 Placebo'], 'description': 'The CT-868 pen injector is a multi-dose, single-participant, disposable pen.', 'name': 'CT-868 Pen Injector', 'type': 'DEVICE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['CT-868 Placebo'], 'description': 'The placebo pen injector is identical and contains the same ingredients except for CT-868.', 'name': 'CT-868 Pen Injector, Placebo', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• CT-868 (protocolSection.armsInterventionsModule.interventions[].name)
• CT-868 Pen Injector, Placebo (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.